Edition:
United States

Conatus Pharmaceuticals Inc (CNAT.OQ)

CNAT.OQ on NASDAQ Stock Exchange Global Market

5.17USD
3:59pm EST
Change (% chg)

$0.01 (+0.19%)
Prev Close
$5.16
Open
$5.18
Day's High
$5.21
Day's Low
$4.99
Volume
96,230
Avg. Vol
80,100
52-wk High
$9.40
52-wk Low
$3.88

Latest Key Developments (Source: Significant Developments)

Conatus Pharmaceuticals reports Q3 revenue of $9.6 million
Wednesday, 1 Nov 2017 04:05pm EDT 

Nov 1 (Reuters) - Conatus Pharmaceuticals Inc :Conatus Pharmaceuticals Inc reports third quarter 2017 financial results and program updates.Q3 revenue $9.6 million.Q3 revenue view $16.1 million -- Thomson Reuters I/B/E/S.Conatus Pharmaceuticals Inc - qtrly ‍net loss per share $0.13.  Full Article

EMA grants Conatus orphan drug designation for IDN-7314 for the treatment of PSC
Wednesday, 18 Oct 2017 04:05pm EDT 

Oct 19 (Reuters) - Conatus Pharmaceuticals Inc :EMA grants Conatus orphan drug designation for IDN-7314 for the treatment of PSC.Conatus Pharmaceuticals - ‍continue to evaluate potential internal, external opportunities with goal of announcing initial pipeline expansion plans later in 2017​.  Full Article

Conatus Pharmaceuticals files for mixed shelf of upto $100 mln
Thursday, 17 Aug 2017 04:45pm EDT 

Aug 17 (Reuters) - Conatus Pharmaceuticals Inc :Conatus Pharmaceuticals Inc files for mixed shelf of upto $100 million - SEC filing.  Full Article

Conatus announces completion of enrollment
Monday, 14 Aug 2017 04:05pm EDT 

Aug 14 (Reuters) - Conatus Pharmaceuticals Inc ::Conatus announces completion of enrollment in encore-NF phase 2B clinical trial of emricasan in patients with NASH fibrosis.  Full Article

Conatus announces effectiveness of exclusive license with Novartis
Thursday, 6 Jul 2017 04:05pm EDT 

July 6 (Reuters) - Conatus Pharmaceuticals Inc -:Conatus Pharmaceuticals - exclusive license with Novartis for global development and commercialization of emricasan has become effective under terms.Conatus Pharmaceuticals - projecting a balance of cash, cash equivalents and marketable securities of between $55 million and $65 million at year-end 2017.Conatus Pharmaceuticals Inc - license became effective on July 5, 2017, upon conatus' receipt of a $7 million payment.Conatus Pharmaceuticals - believes current financial resources sufficient to maintain operations & ongoing clinical development activities through 2019 end.  Full Article

FDA grants Conatus orphan drug designation for idn-7314 for the treatment of PSC
Monday, 26 Jun 2017 07:00am EDT 

June 26 (Reuters) - Conatus Pharmaceuticals Inc ::FDA grants conatus orphan drug designation for idn-7314 for the treatment of PSC.  Full Article

Conatus prices offering of 5.20 mln shares at $5.50/shr
Thursday, 11 May 2017 09:02am EDT 

May 11 (Reuters) - Conatus Pharmaceuticals Inc ::Conatus announces pricing of public offering of common stock.Says public offering of 5.20 million common shares priced at $5.50 per share.Intends to use about $16.7 million of gross proceeds from offering to fund pipeline expansion and for working capital.  Full Article

Conatus Pharmaceuticals Q1 revenue $7.0 million
Thursday, 4 May 2017 04:05pm EDT 

May 4 (Reuters) - Conatus Pharmaceuticals Inc :Conatus Pharmaceuticals reports first quarter 2017 financial results and program updates.Q1 revenue $7.0 million.Q1 revenue view $4.1 million -- Thomson Reuters I/B/E/S.Conatus Pharmaceuticals - current financial resources are sufficient to maintain operations and ongoing clinical development activities through end of 2019.Conatus Pharmaceuticals Inc qtrly net loss at $0.14 per share.Q1 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S.  Full Article

Conatus Pharmaceuticals says appointed Steven Mento as acting principal financial officer on March 16
Tuesday, 21 Mar 2017 04:24pm EDT 

Conatus Pharmaceuticals Inc :Conatus Pharmaceuticals Inc - on March 16, board appointed Steven Mento as company's acting principal financial officer.  Full Article

Conatus Pharma qtrly loss per share $0.35
Wednesday, 15 Mar 2017 04:05pm EDT 

Conatus Pharmaceuticals Inc : Conatus pharmaceuticals reports 2016 financial results and program updates . Q4 revenue $800,000 . Q4 revenue view $1.7 million -- Thomson Reuters I/B/E/S .Qtrly loss per share $0.35.  Full Article

BRIEF-Conatus Pharmaceuticals reports Q3 revenue of $9.6 million

* Conatus Pharmaceuticals Inc reports third quarter 2017 financial results and program updates